The PennZone

BELLEFONTE, Pa. - PennZone -- Treating alcohol misuse remains a major challenge worldwide.  Given the diverse biological processes that contribute to alcohol use disorder, new medications are needed to provide a broader spectrum of treatment options. Some people may respond to a medication that helps with craving, others may respond to a medication that relieves impulsivity, others may respond to a medication that reverses the negative emotional state of withdrawal or protracted withdrawal. Just like any other medical condition, people with alcohol use disorder deserve to have a range of treatment options available to them. Scientists are working to develop a larger menu of pharmaceutical treatments that could be tailored to individual needs.

Actuated Medical's innovative NeuralGlider Injector will enable the delivery of next-generation medications into small targets deep in the brain, to fundamentally change the trajectory of alcohol use disorder and improve outcomes.  The goal is to deliver a therapeutic that will damp down cravings enough for other therapies to have a chance to work.  The therapeutic gets delivered accurately to the target and stays there.

Actuated Medical, Inc. has been awarded a $3 million pre-clinical Phase II Small Business Innovative Research (SBIR) grant from the National Institutes of Health-National Institute on Alcohol Abuse and Alcoholism to develop the "Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS (designer receptors exclusively activated by designer drugs) Therapy in Alcohol Addiction Treatment" which will be commercially recognized as the NeuralGlider Injector.

More on The PennZone

• Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
• Primeindexer Google indexing platform launched by SEO Danmark APS
• Kaltra Introduces New Downward-Spraying Distribution Technology to Boost Microchannel Evaporator Performance
• Talentica Announces Winners of Multi-Agent Hackathon 2026
• Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth

"Many of us know someone who is dealing with an alcohol addiction and have felt helpless as we watched them suffer. That is why we are so excited to develop and commercialize our NeuralGlider Injector technology as it may one day help to offer a more effective treatment option for those afflicted with alcohol use disorder." Maureen L. Mulvihill, Ph.D., Actuated Medical President, CEO, & Co-Founder.

About Actuated Medical, Inc.

Actuated Medical is a Pennsylvania medical device product innovator founded in 2006 on the entrepreneurial idea that electronically controlled motion can solve clinical needs and improve patient outcomes. They are developing products in the areas of neuroscience, critical care, gastroenterology, and pediatrics. Their Actuated Neuroscience Division focuses on developing tools to assist researchers in understanding neurological conditions. Recently, they were awarded a 5-year Contract under the National Institutes of Health (NIH) Blueprint MedTech (BPMT) initiative to assist brain researchers conduct their FDA compliant testing. Actuated has 42 issued patents and 7 FDA 510(k) clearances. They have been the recipient of a 2014 & 2020 SBA Tibbets Awards for SBIR commercialization excellence. Actuated's CEO was the 2020 Life Sciences Pennsylvania CEO of the Year due to the teams Covid PPE pivot.

More on The PennZone

• Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX
• Vesica Health Receives FDA Breakthrough Device Designation for AssureMDx
• Lineus Medical's SafeBreak® Vascular Added to Alliant GPO Contract
• Cancun All Inclusive is ready for Spring Break 2026 with new Resorts, Exclusive Deals, activities and more!
• 66% of US Bankruptcies Are Medical — So Americans Are Building Businesses That Cover Healthcare Emergencies

More information about Actuated neural device innovations.

See www.actuatedneuroscience.com

NIH Disclaimer.

Research reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R44AA030512. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

For more information about this topic, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.

Additional information can be found by visiting:

https://actuatedmedical.com

https://actuatedneuroscience.com